Lyell Immunopharma (NASDAQ:LYEL) Trading 7% Higher

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) traded up 7% during mid-day trading on Friday . The stock traded as high as $12.02 and last traded at $12.02. 5,192 shares were traded during trading, a decline of 99% from the average session volume of 506,213 shares. The stock had previously closed at $11.23.

Several equities research analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Lyell Immunopharma in a research note on Monday, July 12th. They set an “overweight” rating and a $25.00 target price on the stock. Bank of America initiated coverage on shares of Lyell Immunopharma in a research report on Monday, July 12th. They set a “buy” rating and a $25.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Lyell Immunopharma in a research report on Monday, July 12th. They set a “buy” rating and a $30.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of Lyell Immunopharma in a research report on Monday, July 12th. They set an “overweight” rating and a $22.00 price target for the company.

The stock’s fifty day moving average price is $14.86.

Hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. acquired a new stake in Lyell Immunopharma in the 2nd quarter valued at about $3,132,000. GSA Capital Partners LLP acquired a new stake in Lyell Immunopharma in the 2nd quarter valued at about $495,000. Baillie Gifford & Co. acquired a new stake in Lyell Immunopharma in the 2nd quarter valued at about $4,204,000. Eagle Health Investments LP acquired a new stake in shares of Lyell Immunopharma during the 2nd quarter worth approximately $1,624,000. Finally, Mic Capital Partners Public US IM LLC acquired a new stake in shares of Lyell Immunopharma during the 2nd quarter worth approximately $21,437,000. Institutional investors own 30.84% of the company’s stock.

Lyell Immunopharma Company Profile (NASDAQ:LYEL)

Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.

Further Reading: What is the Euro STOXX 50 Index?

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.